Date of Deposit: June 21, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schneider et al.

Examiner: TBA

Atty. Dkt. No. BR-036 PUS-01

Serial No.: TBA

Art Unit: TBA

Filing Date: June 21, 2006

For: ASSEMBLY OF GAS-FILLED MICROVESICLE WITH ACTIVE COMPONENT FOR

CONTRAST IMAGING

Certificate of Express Mail Under 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated below, and is addressed to:

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: June 21, 2006

Signature: Pamele gew

Pamela Gewirt

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 AND 1.98

Sir:

It is respectfully requested that the accompanying Information Disclosure Statement be considered during the pendency of the prosecution of the concurrently filed application entering the national stage filing of corresponding international application number PCT/IB2004/004233 pursuant to § 1.97(b):

X (1) within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d)


X (2) within three months of the date of entry of the national stage as set forth in § 1.491 in an international application

(3) before the mailing of a first Office action on the merits; or

(4) before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

All references, pursuant to 37 CFR§1.98, are identified on the forms PTO/SB/08A and 08B, and some are repeated in the PCT International Search Report for corresponding international application number PCT/IB2004/004233. A copy of the PCT International Search Report is enclosed.

Date of Deposit: June 21, 2006



Under 37 CFR § 1.17(p), the fee of \$180.00 is not believed to be due with the filing of this Information Disclosure Statement as it is not being filed under 37 C.F.R. § 1.97(c) or (d). However, if any fees are deemed necessary, the Director is hereby authorized to charge such fees to Deposit Account No. 50-2168.

June 21, 2006

Date

Respectfully submitted.

M. Caragh Noone Attorney for Applicant

Reg. No.: 37,197

Bracco Research USA Inc. 305 College Road East Princeton, NJ 08540

(609) 514-2454 (609) 514-2446



PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number TBA. INFORMATION DISCLOSURE Filing Date June 21, 2006 STATEMENT BY APPLICANT First Named Inventor Michel SCHNEIDER (Use as many sheets as necessary) Art Unit **TBA** Examiner Name **TBA** Attorney Docket Number Sheet 2 BR-036 PUS 01 of 1

			U.S.	PATENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where
Пишаль		Number-Kind Code ² (Fknown)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA	US 4,276,885 B1	07-07-1981	Rasor Associates, Inc.	
	AB	US 4,888,398 B1	12-19-1989	Battelle Memorial Institute	
	AC	US 5,271,928 B1	12-21-1993	Sintetica S.A.	
	AD	US 5,413,774 B1	05-09-1995	Bracco International B.V.	
	ΑE	US 5,445,813 B1	08-29-1995	Bracco International B.V.	
	AF	US 5,545,395 B1	08-13-1996	Bracco Research S.A.	
	AG	US 5,531,980 B1	07-02-1996	Bracco International B.V.	
	AH	US 5,556,610 B1	09-17-1996	Bracco Research S.A.	
	Al	US 5,562,099 B1	10-08-1996	Massachusetts Institute of Technology; The Penn State Research Foundation	
-	AJ	US 5,597,549 B1	01-28-1997	Bracco International B.V.	
	AK	US 5,605,673 B1	02-25-1997	Alliance Pharmaceutical Corp.	
	AL	US 5,711,933 B1	01-27-1998	Bracco International B.V.	
	AM	US 5,827,504 B1	10-27-1998	Bracco Research S.A.	
	AN	US 6,139,819 B1	10-31-2000	ImaRx Pharmaceutical Corp.	
	AO	US 6,221,337 B1	04-24-2001	Nycomed Imaging AS	
	AP	US 6,331,289 B1	12-25-2001	Bracco Research S.A.	
	AQ	US 6,333,021 B1	12-18-2001	Nycomed Imaging AS	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	INO.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			T ⁶			
	BA	EP 0130935 B1	04-15-1987	Battelle Memorial Institute					
ВВ		EP 0324938 B1	11-18-1993	Molecular Biosystems, Inc.					
	BC	EP 0554213 B1	01-15-1997	Bracco International B.V.					
	BD	EP 0804251 B1.	09-25-2002	Bracco Research S.A.					
	BE	EP 1228770 A1	08-07-2002	Bracco Research S.A.					
	BF	EP 1228770 B1	07-13-2005	Bracco Research S.A.					
	BG	WO 87/03891	07-02-1987	Battelle Memorial Institute					
	ВН	WO 91/15244 A2	10-17-1991	Sintetica S.A.					
	ВІ	WO 94/09829 A1	05-11-1994	Sintetica S.A.					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USpTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, alexandria, VA 22313-1450.

2

of

Sheet

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

BR-036 PUS 01

Complete if Known Substitute for form 1449/PTO Application Number **TBA** INFORMATION DISCLOSURE Filing Date June 21, 2006 STATEMENT BY APPLICANT First Named Inventor Michel SCHNEIDER (Use as many sheets as necessary) Art Unit **TBA Examiner Name** TBA 2 Attorney Docket Number

		FORI	EIGN PATEN	IT DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
IIIIuais		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			T ⁶
	BJ	WO 94/28873 A1	12-22-1994	Unger et al.		
	BK	WO 95/23615 A1	09-08-1995	Nycomed Imaging AS		
	BL	WO 97/29783 A1	08-21-1997	Nycomed Imaging AS		
	ВМ	WO 98/18501 A2	05-07-1998	Nycomed Imaging AS	†	
	BN WO 99/39738 A1		08-12-1999 Bracco Research S.A.			
	ВО	WO 99/53963 A1	10-28-1999	Nycomed Imaging AS		
	BP	WO 99/55383 A2	11-04-1999	Nycomed Imaging AS		
	BQ	WO 02/055544 A2	07-18-2002	Dyax Corp.		
	BR	WO 03/015831 A1	02-27-2003	Bristol-Myers Squibb Pharma Company		
	BS	WO 03/074005 A2	09-12-2003	Dyax Corp. and Bracco International B.V.		
	ВТ	WO 03/084574 A1	10-16-2003	Bracco International B.V. and Dyax Corp.		
	BU	WO 04/069284 A2	08-19-04	Bracco Research S.A.		
	BV	WO 04/069284 A3	08-19-04	Bracco Research S.A.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USpTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, alexandria, VA 22313-1450.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subst	titute for form 1449/PTO			Complete if Known		
				Application Number	TBA A A A A A A A A A A A A A A A A A A	
	ORMATION DI			Filing Date	June 21, 2006	
SIA	ATEMENT BY A	APP	LICANT	First Named Inventor	Michel SCHNEIDER	
	(Use as many sheets as	neces	sarv)	Art Unit	ТВА	
	(occus many choose ac		,,,	Examiner Name	TBA	
Sheet	1	of	1	Attorney Docket Number	BR-036 PUS 01	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate)						
	CA	KATHERINE C. GRABAR et al: "Preparation and Characterization of Au Colloid Monolayers" Analytical Chemistry, Vol. 67, No. 4, February 15, 1995, pp. 735-743				
		M. MALMSTEN, "Surfactants and Polymers in Drug Delivery", 2002, Ch. 2, pp. 19-50, Ch. 4, pp. 87-131, Marcel Dekker Inc. Ed.				
		G.W. KABALKA et al., "Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver", Magnetic Resonance in Medicine, 1988, pp. 89-95, Vol. 8, Academic Press, Inc.				
	CD Edited by R. R. C. New "Liposomes, a practical approach", 1989, pp. 45-55, Oxford University Press, Oxford, New York, Tokyo					
	CE	PCT Search Report for PCT/IB2004/004230, mail date 05-30-2005				
	CF	PCT Written Opinion of the ISA, mail date 05-30-2005				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant,

Applicant's unique citation designation number (optional).

Applicant is unique citation designation number (optional).

Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, alexandria, VA 22313-1450.